NCT01790828View on ClinicalTrials.gov

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

CompletedOBSERVATIONAL
Enrollment

42

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Hemophilia A
Interventions
DRUG

Xyntha : coagulation factor IIIV (recombinant)

Xyntha will be administered according to physician's discretion.

Trial Locations (4)

152-834

Yonsei Rehabilitation Clinic, Guro-gu

138-879

Kim Hugh Chul Internal Medicine Clinic, Songpa-gu

632-739

Pusan National University Hospital, Busan

134-727

Kyung Hee University Hospital at Gangdong, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01790828 - Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A | Biotech Hunter | Biotech Hunter